Blogs | MedChemExpress

AMG 511 is an Orally Active pan-PI3K Inhibitor

AMG 511 is a potent and selective class I PI3K inhibitor. Suppresses PI3K signaling. Decreases in phosphorylated AKT at Ser473 in a dose-dependent manner.
TAK-683 is a Potent Metastin/GPR54 Agonist

TAK-683 is a full KISS1R agonist (IC50=170 pM) with improved metabolic stability. It has the potential for the study of hormone-dependent prostate cancer.
ARCC-4 is a Highly Potent PROTAC Androgen Receptor Degrader

ARCC-4 is a low-nanomolar AR degrader, and effectively degrades clinically relevant AR mutants associated with antiandrogen therapy.
M2698 is an Orally Active, ATP-Competitive, Selective, Dual p70S6K and Akt Inhibitor

M2698 is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with anti-cancer activity. M2698 can cross the blood-brain barrier.
BAY1082439 is an Orally Active and Selective PI3Kα/β/δ Inhibitor

BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor, which is highly effective in inhibiting Pten-null prostate cancer growth.
DC-5163, a GAPDH Inhibitor, Inhibits Glycolysis Pathway and Induces Apoptosis

DC-5163 is a potent GAPDH inhibitor, can inhibit glycolysis pathway partially. DC-5163 selectively inhibits cancer cell proliferation and induces apoptosis.
TL13-12 is a Selective ALK-PROTAC Degrader

TL13-12 can induce receptor tyrosine kinase anaplastic lymphoma kinase degradation in non small cell lung cancer cells. PROTAC ALK degrader.
TP3011 is a Potent Topoisomerase-1 Inhibitor with Anti-tumor Effect

TP3011 is a potent DNA topoisomerase I inhibitor. Antitumor activities.Active metabolite of TP3076. TP3011 inhibits cancer cell proliferative activities.
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation

CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties.
TL13-112 is a PROTAC Degrader of ALK

TL13-112 is a selective ALK-PROTAC degrader and inhibits ALK activity. TL13-112 is comprised of the conjugation of Ceritinib and the ligand pomalidomide .

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (18)